| 微生态制剂治疗肝性脑病的研究进展 |
| |
| 引用本文： | 陈海艳,涂燕云.微生态制剂治疗肝性脑病的研究进展[J].大众科技,2014(10):114-116. |
| |
| 作者姓名： | 陈海艳 涂燕云 |
| |
| 作者单位： | 1. 广西中医药大学,广西 南宁,530001
2. 广西中医药大学附属瑞康医院,广西 南宁,530001 |
| |
| 摘 要： | 肝性脑病（hepatic encephalopathy,HE）是由急、慢性肝功能衰竭或各种门-体分流（porto-systemic venous shunting,PSS）引起的以代谢紊乱为基础的、并排除了其它已知脑病的中枢神经系统失调综合征。常以神经精神症状,如性格改变、行为异常、智力减退等为突出表现,发病机制复杂,但经过合理、及时治疗后,该综合征具有潜在的可逆性。如何选择合理有效的药物预防和防止肝性脑病复发,逆转患者的精神神经系统失调已经成为目前研究热点。笔者针对目前微生态制剂药物组成、作用机制、临床疗效及其对治疗肝性脑病的研究进展做一综述。
|
| 关 键 词： | 微生态制剂 肝性脑病 |
Progress in developing probiotics therapy of hepatic encephalopathy |
| |
| Abstract: | Hepatic encephalopathy was result as acute or chronic liver failure or porto-systemic venous shunting which result in syndrome of central nervous system disorders based on metabolic disorders excluding other specific encephalopathies. Usually, it stands out with neuropsychiatric symptoms, such as character changing, behavior disorder, hypophrenia, etc. The pathogenesis is complicated, while with Reasonable and timely treatment, the syndrome may be reversible. Currently, the hot point in this field focuses on how to select reasonable and efficient medication to prevent the recurrence of hepatic encephalopathy and reverse the disordered neuropsychiatric symptoms. This review summarized probiotics drug component, pharmacological mechanism, clinical efficacy and applications in Hepatic encephalopathy. |
| |
| Keywords: | Probiotics hepatic encephalopathy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
